Aspirin - From prevention to targeted therapy

New England Journal of Medicine

Volumn 367, Issue 17, 2012, Pages 1650-1651

  Pasche, Boris ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADJUVANT THERAPY; APOPTOSIS; CANCER CELL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG USE; EDITORIAL; ENZYME ACTIVITY; ENZYME SUBUNIT; HUMAN; METASTASIS; MICROMETASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH; UNITED STATES;

EID: 84867791528     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1210322     Document Type: Editorial

References (10)

1. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
2. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007;25:3456-61.
3. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29:11-6.
4. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. JAMA 2012;307:1383-93.
5. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
6. Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012;106:1564-70.
7. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
8. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
9. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18:2257-68.
10. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.